← Back to Search

MoveMend Health for Transplant Patients

N/A
Recruiting
Led By Steve Vanlew
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Orientation Log > 25
Status post kidney or liver transplant this admission
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to month 6 post-operation
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to see if a new software program, MoveMend Health, can be helpful for patients who have had liver and kidney transplants. Researchers will look at how many patients join the program

Who is the study for?
This trial is for English-speaking patients who have recently undergone a kidney or liver transplant and are in the hospital. They must be mentally oriented, not delirious, and have a doctor's order for occupational therapy.
What is being tested?
The study is testing MoveMend Health software as an extra activity during regular occupational therapy sessions for patients recovering from liver or kidney transplants to see if it's doable and helpful.
What are the potential side effects?
Since this trial involves exercise through a software program, potential side effects may include muscle soreness or strain. The safety of the program will also be monitored throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My mental orientation score is above 25.
Select...
I have had a kidney or liver transplant during this hospital stay.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to month 6 post-operation
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to month 6 post-operation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Adverse Events
Percentage of Participants who Adhere to Intervention
Percentage of Participants who Complete Exercise Program
+1 more
Secondary study objectives
Change in Activity Measure for Post-Acute Care (AMPAC) Score
Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score
Change in Grip Strength
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients Hospitalized following Kidney or Liver TransplantExperimental Treatment1 Intervention
Patients in the study will be introduced to the exercise software program and provided with a demonstration. Measurements will be taken at baseline (post-operation) and at the final study visit. Participants will remain in the study until the end of their hospital stay, typically no longer than 6 months post-operation.

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,415 Previous Clinical Trials
856,052 Total Patients Enrolled
Steve VanlewPrincipal InvestigatorNYU Langone Health
~20 spots leftby Dec 2025